Cargando…

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review

Objectives: The aim of this study was to review reimbursement environment as well as pricing and reimbursement requirements for drugs in selected Central and Eastern Europe (CEE) countries. Methods: A questionnaire-based survey was performed in the period from November 2016 to March 2017 among exper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawalec, Paweł, Tesar, Tomas, Vostalova, Lenka, Draganic, Pero, Manova, Manoela, Savova, Alexandra, Petrova, Guenka, Rugaja, Zinta, Männik, Agnes, Sowada, Christoph, Stawowczyk, Ewa, Harsanyi, Andras, Inotai, Andras, Turcu-Stiolica, Adina, Gulbinovič, Jolanta, Pilc, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741607/ https://www.ncbi.nlm.nih.gov/pubmed/29326583 http://dx.doi.org/10.3389/fphar.2017.00892

Ejemplares similares

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Comparison of Cardiovascular Medicines Prices in Four European Countries
por: Mitkova, Zornitsa, et al.
Publicado: (2020)

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria
por: Tkachova, Oksana, et al.
Publicado: (2019)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
por: Manova, Manoela, et al.
Publicado: (2018)

Potential Cost-Savings From the Use of the Biosimilars in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2020)

Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland
por: Kamusheva, Maria, et al.
Publicado: (2021)

Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2017)

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
por: Mitkova, Zornitsa, et al.
Publicado: (2019)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts
por: Inotai, Andras, et al.
Publicado: (2018)

Influence of COVID-19 on Health-Related Quality of Life and the Perception of Being Vaccinated to Prevent COVID-19: An Approach for Community Pharmacists from Romania and Bulgaria
por: Turcu-Stiolica, Adina, et al.
Publicado: (2021)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
por: Russel-Szymczyk, Monika, et al.
Publicado: (2019)

Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2020)

The EEC at the end of the seventies : Western European integration in the new world economic environment /
por: Inotai, András
Publicado: (1979)

Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment
por: Zemplényi, Antal, et al.
Publicado: (2023)

A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2018)

Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Editorial: Advances in the potential treatments of gastrointestinal and liver diseases: addressing the public health burden
por: Turcu-Stiolica, Adina, et al.
Publicado: (2023)

Antibiotic Resistance, Still a Global Challenge
por: VOICU, MIRELA NICOLETA, et al.
Publicado: (2021)

Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries
por: Turcu-Stiolica, Adina, et al.
Publicado: (2021)

Marketing research on the angiotensin-converting enzyme inhibitors antihypertensive medicines
por: BOBOIA, ANAMARIA, et al.
Publicado: (2017)

Cost-Utility Analysis of Incobotulinumtoxin-A Compared With Conventional Therapy in the Management of Post-Stroke Spasticity in Romania
por: Turcu-Stiolica, Adina, et al.
Publicado: (2020)

Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center
por: Turcu-Stiolica, Adina, et al.
Publicado: (2021)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings
por: Petykó, Zsuzsanna Ida, et al.
Publicado: (2021)

Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives
por: Kaló, Zoltán, et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on Health-Related Quality of Life, Anxiety, and Training Among Young Gastroenterologists in Romania
por: Ungureanu, Bogdan Silviu, et al.
Publicado: (2020)

Personal Autonomy as Quality of Life Predictor for Multiple Sclerosis Patients
por: Padureanu, Rodica, et al.
Publicado: (2020)

Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kryst, Joanna, et al.
Publicado: (2015)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
por: Holko, Przemysław, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mj04l5t3c0atorq2ham97785ta